HUANGSHAN-TOURISM
14.3.2022 12:38:06 CET | Business Wire | Press release
Huangshan again captured the imagination of guests at the 2022 ITB Berlin, the world's largest travel trade fair. This year’s virtual ITB Berlin, held from March 8 to 10, saw experts and industry representatives from around the world explore and discuss digital, resilient, and responsible solutions for the global tourism industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220314005401/en/
At the event, Huangshan Tourism Development Co., Ltd. (Huangshan Tourism) held a press conference and multimedia presentation to showcase the many attractions of Huangshan, including its prime location, unique landscapes, rich cultural heritage, and well-developed infrastructures to support local tourism.
The presentation covered six highlights that make Huangshan so appealing as a travel destination.
“Travel in Huangshan” showed its access to a transport network connecting key travel hubs in China. “The Beauty of Huangshan” put the spotlight on the spectacular scenery of Huangshan, from mountain landscapes and its characteristic pine trees to the nearby Taiping Lake. “The Food of Huangshan” gave a taste of the local Huizhou cuisine, one of China’s eight major cuisines. "Accommodation in Huangshan" provided an overview of the high-standard international tourist lodging. “Gifts from Huangshan" gave a glimpse of the unique local presents. Finally, “Culture in Huangshan” introduced the audience to the rich range of cultural and creative products that embody the handicraft, heritage, and traditions of the region.
The immersive format of the event and images of Huangshan Mountain and surrounding areas left a striking visual impact on the audience, again stimulating interest in Huangshan as a world-class travel destination that epitomizes the very best of China’s natural beauty and rich cultural heritage.
About Huangshan Tourism
Huangshan Tourism is one of China’s leading listed tourism companies. It covers a wide scope of business in and around the Mount Huangshan Scenic Area in China’s Anhui Province, from scenic spots and hotels to retail, catering, travel agencies, rural tourism, and other services.
Huangshan Tourism is committed to telling the story of Huangshan, Huizhou culture, and promoting the area as a top destination for both domestic and international tourists. The company carries out extensive overseas publicity and promotional activities, with over 150,000 followers across Facebook, Twitter, and Instagram. On New Year’s Day and during the Spring Festival this year, Huangshan Tourism once again caught the attention of global audiences with activities in Times Square in New York and Trafalgar Square in London.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220314005401/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom